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Cancer is an extremely complex disease that involves the interaction of biological 
pathways on a number of levels. Activation of the individual pathways does not necessarily 
occur in an independent fashion through parallel linear routes, but operates through large 
and complex networks of interacting pathways. Interactions between pathways can occur 
at a number of different levels and can interact directly, e.g. via phosphorylation events or 
indirectly, e.g. via regulation of gene expression. 
In addition to understanding the interaction of pathways within a cell, it is clear that 
cancer cells do not exist within a vacuum. They respond to signals from outside of the 
individual cell, between different types of cell within a tissue (e.g. epithelial cells responding 
to signals generated from endothelial or stromal cells), and with stimuli external to the tissue, 
e.g. hormones, etc. Therefore cancer can be considered to be an extremely complicated 
system, one in which when one key node is blocked by use of an antineoplastic agent, for 
example, has the opportunity to re-route the signaling to overcome the block.
Most cancer researchers use rather reductionist approaches and focus their studies 
either on a particular gene of interest, or a particular pathway. The ability that we now have 
through the generation of “omics” data to provide data on multiple pathways simultaneously 
means that we need a paradigm shift in cancer research. The ability to generate several 
types of “omics” data from each individual cancer specimen will provide much more 
information about the system in general. This necessitates the ability to provide analytes 
of different types to be used in individual “omics” platforms to generate data on genome 
sequence, DNA copy number, epigenomic, transcriptomic, proteomic, and metabolomic 
data. The data then needs to be integrated to identify the key genes and pathways driving 
an associated phenotype, such as drug response or clinical outcome.
Tissue banks may play a key role in this shift in our approach to the characterization 
of cancer by not only supplying human biosamples to researchers using complimentary 
technologies, but also providing a platform for the data on an individual patient to be 
collated and correlated with clinical information.
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The Chernobyl Tissue Bank was established in 1998 and designed with a systems biology 
approach to radiation-induced thyroid cancer in mind. This paper sets out the strategy 
for the development of the CTB, and, in particular, the substantial contribution made by 
Ukraine to its success.
The Chernobyl Tissue Bank – the paradigm for a cancer resource 
designed for systems biology
The CTB has been funded by four sponsors (the National Cancer Institute of the US, 
the European Commission (EC), the Sasakawa Memorial Health Foundation of Japan 
(SMHF) and the World Health Organization (WHO)) and is supported by two of the 
countries most affected by fallout from the reactor accident, Ukraine and the Russian 
Federation.  
In the early 1990s, a number of projects studying the effect of the Chernobyl accident 
were funded by the four sponsors listed above. The increase in thyroid cancers in children 
and adolescents in Belarus and Ukraine had been confirmed in a number of publications 
[1,2]. By 1995, it was becoming apparent that several European research groups were 
unknowingly receiving material from the same patients for research, and that there were 
discrepancies in the pathological diagnoses being applied to the same tumor. Subsequently, 
a report to the EC confirmed that there had indeed been considerable overlap since 1995 
among a number of EC-funded molecular biology projects [3]. It was then recognized that 
a cooperative tissue bank would reduce the duplication of research effort and provide 
better scientific data on the health effects of the Chernobyl accident. Following agreement 
on the various protocols, the Chernobyl Tissue Bank officially started collecting material 
on October 1, 1998. The full history and detail on the ethics and governance of the project 
have already been published [4].
Study cohort 
The CTB study cohort comprises all patients with thyroid carcinomas and cellular 
follicular adenomas from the contaminated oblasts (the Russian and Ukrainian equivalent 
of a US state) of the Russian Federation (Bryansk, Kaluga, Tula, and Oryol) and Ukraine 
(Kiev, Kiev City, Cherkassy, Chernigov, Rovno, Zhitomyr) who were born on or after April 
26, 1967 (i.e., aged under 19 years at the time of the Chernobyl accident) and operated 
on or after the October 1, 1998. In addition, a number of cases have been collected from 
other areas of Ukraine, relatively less contaminated by radioactive fallout. The collection 
currently comprises 4,288 cases of thyroid cancer and cellular follicular adenoma from 
patients who were under 19 years at the time of the Chernobyl accident; 2,267 of these are 
from Ukraine. Frozen material is available on 1,727 out of the 2,267 cases from Ukraine, and 
DNA and RNA has already been extracted from a quarter of these cases. Collection of blood 
samples began in late 1999 and samples of serum and whole blood have been collected 
from around 950 Ukrainian patients.  One important feature of the project is that it also 
collects biosamples from patients resident in the areas of Ukraine and Russia exposed to 
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radioactive fallout, but who were not exposed to radioiodine, as they were born more 
than 9 months after the accident. These cases form an age- and residency-matched 
cohort of patients who develop spontaneous thyroid neoplasia. This is the ideal cohort for 
comparison with those who were exposed to radioiodine in 1986. The current number of 
cases in this valuable cohort is 379 (245 with a diagnosis of cancer, of which 124 are from 
Ukraine). This number is much lower than those exposed to radioiodine – the incidence of 
thyroid cancer being approximately the same as the background spontaneous rate from 
uncontaminated regions – of the order of 1 per million per year.
The current project therefore consists of two banks of biological material and information 
comprising:
 • Snap frozen and formalin fixed, paraffin embedded samples from tumor, normal tissue 
and, where possible, metastatic tissue from postoperative specimens, 
 • nucleic acids extracted from these specimens, 
 • vials of serum from patients whose thyroid tissue is held in the bank, 
 • samples of whole blood, 
 • DNA extracted from blood,  
 • Results from research projects supplied with samples from the CTB. 
The Ukrainian contribution to the project represents 64% of the total.
Data management within the CTB
The data management infrastructure for the CTB was designed to facilitate a systems 
biology approach to thyroid cancer. It comprises two separate databases, plus an integrated 
database that serves as a portal for researchers to access information on samples and data 
held, and to apply for access to both data and samples (Fig. 6.1).
One, centralized web-accessible database, held on secure servers at Imperial College 
London holds anonymised information on donors to the CTB and the biological samples 
donated by them. Regular, automated transfer of patient data back to secure servers in 
Ukraine and Russia ensures that each center has a local mirror copy. 
Detailed standard operating procedures for the collection and documentation of 
specimens and blood samples have been agreed upon with professional staff involved 
in the collection of material, and ethical standards agreed upon with the relevant 
authorities, conforming to the requirements of each country involved and those of the 
funding organisations.   Each donor is identified by a unique alphanumeric code. Samples 
from each donor are identified by suffixes to this code enabling the specimens and any 
derivatives from them to be linked to the tissue block they were derived from and the 
individual donor. Tissue and blood samples, and extracted materials are recorded within 
tables in the CTB database. The database schema allows easy transfer of data between 
different database systems such as IBM DB2, Oracle, Microsoft SQL Server, MySQL, and 
PostgreSQL. 
The samples database holds relevant information on the patient (date of birth, date of 
operation, sex, oblast of residence at the time of the accident and operation) together with 
pathological information and location coordinates for each sample of tissue, DNA or RNA 
138
Chapter 6
extracted from tissue, and blood, serum and DNA extracted from blood, and information 
on the quality assurance of these derivatives is also recorded within the samples database. 
Dosimetry information for each patient has been provided in collaboration with Professor 
Ilya Likhtarov (see Chapter 2). 
Security and integrity of the data in the CTB Data Warehouse is of paramount importance. 
With regards to the Samples database and corresponding front-end, the access to data 
sets is appropriately restricted according to a country (e.g. Ukraine, Russia) and a role (e.g. 
pathologist, lab technician, administrator) to which a user belongs. Integration of the 
Samples database with the rest of the system and transfer of data between different elements 
of the overall CTB Warehouse are submitted to the same strict security requirements 
and are designed to minimize the risks of data loss or theft. Regular, time and place 
restricted updates of the Integrative database from the Samples and Research databases 
provide the up-to-date link between the research data and the key clinical-data elements 
required by a researcher.
Figure 6.1.  The CTB data warehouse combines the Samples, Research and Integrative Databases, 
Management and Search Modules with corresponding front-ends/interfaces. The system was 
developed with assistance from the Bioinformatics Support Services (BSS) at Imperial College, and 
continued close cooperation is essential for the smooth and secure integration of all the components 
of the overall system. Access to further samples and to information stored in the research database 
from the use of previous samples in research from the same patient is provided by the CTB portal.
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The CTB Portal (https://cisbic.bioinformatics.ic.ac.uk/ctb/html_ctb_public/)
The CTB Portal provides on-line access to the resources of the CTB. Accessible either 
directly or from the CTB web site, the Portal gives access to a simple, but powerful, 
search facility that allows a researcher to search the database and check if samples are 
available that match the requirements for their study. Biomaterials are defined by: the 
type of thyroid tumor (from the consensus diagnosis of the Pathology Panel); the origin 
of the sample – blood, tumor tissue or normal tissue; the type of sample – FFPE section; 
extracted DNA or RNA; and key patient information such as age at exposure, residency, 
etc. The results of the search show the number of cases that match the criteria and the 
number of samples that are available. The system went live on the 25th anniversary of the 
Chernobyl accident. Representative screenshots of the Portal and the search filter are 
shown in Figure 6.2. 
The PI is guided through the on-line application process to request samples. 
Management tools embedded within the Portal, and accessible only by the secretariat, 
facilitate the processing of applications and tracking progress through the review and 
approvals process. Once the applicant has submitted their application on-line, the 
secretariat checks that the application is complete. The status of the application is altered as 
Figure 6.2. Representative screenshots of the CTB portal.  (2A) Login entry page.  (2B) User 
searches samples by selecting criteria of interest. As search filters are selected, numbers of samples 
matching criteria are shown. (2C) Representative search results page showing available samples, 
search criteria and additional data available for sharing.
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it progresses through each stage of the process and an e-mail is automatically sent to the PI 
acknowledging each change of status: (submitted for review, more information required, 
etc.). The software automatically compiles the various sections of the application into a 
PDF. The secretariat then forwards this to the External Review Panel for assessment of the 
scientific quality of the project requesting access.  
The integrative database produces a comprehensive list of all the cases identified that 
match the search criteria entered by the applicant. This listing is available only to the 
secretariat and is a significant step in the automation of the process of selecting appropriate 
samples for a project. The process can never be totally automated and expert oversight 
of the pathological information will always be required. However, the initial screening 
facilitates this procedure.
The CTB Portal also provides access to the Data Warehouse both for PIs to upload data 
from their approved CTB projects and for other researchers to be able to see if data is 
available linked to the cases they have selected.
Use of CTB samples in research
Biospecimens from the CTB have been provided to the major research groups involved 
in the studies of the consequences of the Chernobyl accident. Information on the projects 
receiving biosamples can be found at http://www.chernobyltissuebank.com/research.
html.  Thirty projects have been approved for access to date; 11,901 samples have already 
been released to these projects. Of these, 11,498 were provided from the Ukrainian section 
of the CTB. Scientific evaluation of each project is provided by the CTB’s External Review 
Panel (ERP) and the outcome of the review and, where appropriate, any feedback from the 
ERP is provided to the applicant.
This approach provides a basis that fosters international collaboration and reduces the 
chance of competition and even friction between groups in their requests for this material. 
Researchers who obtain material from the resource agree to provide the results of their 
investigation on a case-by-case basis to enable combined analysis to be carried out at a 
later date. The provision of extracted nucleic acid from thyroid tissue, rather than each 
researcher being provided with a small piece of tissue, maximises the amount of data 
that can, potentially, be obtained from a single operative specimen and enables multiple 
molecular biological studies to be carried out for each case. The median number of projects 
supplied by material from a single case at present is 4 with some being used in more than 
9 projects. Details of the publications resulting from material supplied by the project are 
listed on the project website (www.chernobyltissuebank.com/papers.html). Data on Copy 
Number Alteration, mRNA expression, SNP and mutation/translocation of thyroid cancer 
key oncogenes RET and BRAF, is already available for over a quarter of the cases, with 
miRNA array and methylation DNA array data being made available through the EU funded 
EpiRadBio project. Similar data will also be available soon from patients enrolled in the 
Ukrainian-American Cohort.
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Results of Research studies
The pathology of all cases submitted to the CTB is reviewed by an International Pathology 
Panel. Their review of the cases has suggested a new classification for thyroid cancer [5] 
and has shown that the latency affects the morphological subtype and aggressiveness of 
papillary cancers [6] with the frequency of the solid subtype falling from 24 to 6% over the 
first two decades after the accident, and a similar decline in the frequency of extrathyroid 
extension and lymph node metastases [7]. A more detailed explanation of the pathological 
features can be found in Chapters 4 and 5 in this book.
The results of molecular biological studies that have used material from the Chernobyl 
Tissue Bank are included in Chapter 7 in this book. An abstract of all projects authorized to 
use material from the CTB, and links to papers that have resulted from these projects, are 
available on the project website (www.chernobyltissuebank.com).
Thus, we can conclude that understanding the major drivers in tumour growth will 
depend increasingly on being able to take a systems biology approach, rather than an 
individual gene or analytical platform approach. It is already evident from the literature 
that a change in copy number at the DNA level does not always result in an increase in RNA 
expression of all of the genes coded for by the amplified region, and that identifying critical 
nodes within networks of converging signalling pathways will be necessary to understand 
the functional biology of cancer [8]. Collating all of the research data generated from the 
samples donated by those affected by the Chernobyl accident is a challenge. By collating 
the data in a central resource, the CTB will facilitate not only projects that require access to 
samples alone, but also projects that wish to link their results with data already available. 
Tissue banks are likely to be key players in this type of cancer research in future and should 
be designed from the outset to facilitate this aim.
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